Effect of K-ATP channel blocker glibenclamide on PACAP38-induced headache and hemodynamic
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Effect of K-ATP channel blocker glibenclamide on PACAP38-induced headache and hemodynamic. / Kokoti, Lili; Al-Karagholi, Mohammad Al-Mahdi; Elbahi, Fatima Azzahra; Coskun, Hande; Ghanizada, Hashmat; Amin, Faisal Mohammad; Ashina, Messoud.
I: Cephalalgia, Bind 42, Nr. 9, 2022, s. 846-858.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Effect of K-ATP channel blocker glibenclamide on PACAP38-induced headache and hemodynamic
AU - Kokoti, Lili
AU - Al-Karagholi, Mohammad Al-Mahdi
AU - Elbahi, Fatima Azzahra
AU - Coskun, Hande
AU - Ghanizada, Hashmat
AU - Amin, Faisal Mohammad
AU - Ashina, Messoud
PY - 2022
Y1 - 2022
N2 - Objective To determine whether glibenclamide, a non-selective adenosine 5 '-triphosphate-sensitive K+ (K-ATP) channel blocker, attenuates pituitary adenylate cyclase-activating polypeptide-38 (PACAP38)-induced headache and vascular changes in healthy volunteers. Methods In a double-blind, randomized, placebo controlled and crossover design, 22 healthy volunteers were assigned to receive an intravenous infusion of 10 picomole/kg/min pituitary adenylate cyclase-activating polypeptide-38 over 20 minutes followed by oral administration of 10 mg glibenclamide or placebo. The primary endpoint was the difference in incidence of headache (0-12 hours) between glibenclamide and placebo. The secondary endpoints were a difference in area under the curve for headache intensity scores, middle cerebral artery velocity (V-meanMCA), superficial temporal artery diameter, radial artery diameter, heart rate, mean arterial blood pressure and facial skin blood flow between the two study days. Results Twenty participants completed the study. We found no difference in the incidence of pituitary adenylate cyclase-activating polypeptide-38-induced headache after glibenclamide (19/20, 95%) compared to placebo (18/20, 90%) (P = 0.698). The area under the curve for headache intensity, middle cerebral artery velocity, superficial temporal artery diameter, radial artery diameter, facial skin blood flow, heart rate and mean arterial blood pressure did not differ between pituitary adenylate cyclase-activating polypeptide-38-glibenclamide day compared to pituitary adenylate cyclase-activating polypeptide-38-placebo day (P > 0.05). Conclusions Posttreatment with 5 '-triphosphate-sensitive K+ channel inhibitor glibenclamide did not attenuate pituitary adenylate cyclase-activating polypeptide-38-induced headache and hemodynamic changes in healthy volunteers. We suggest that pituitary adenylate cyclase-activating polypeptide-38-triggered signaling pathway could be mediated by specific isoforms of sulfonylurea receptor subunits of 5 '-triphosphate-sensitive K+ channels and other types of potassium channels.
AB - Objective To determine whether glibenclamide, a non-selective adenosine 5 '-triphosphate-sensitive K+ (K-ATP) channel blocker, attenuates pituitary adenylate cyclase-activating polypeptide-38 (PACAP38)-induced headache and vascular changes in healthy volunteers. Methods In a double-blind, randomized, placebo controlled and crossover design, 22 healthy volunteers were assigned to receive an intravenous infusion of 10 picomole/kg/min pituitary adenylate cyclase-activating polypeptide-38 over 20 minutes followed by oral administration of 10 mg glibenclamide or placebo. The primary endpoint was the difference in incidence of headache (0-12 hours) between glibenclamide and placebo. The secondary endpoints were a difference in area under the curve for headache intensity scores, middle cerebral artery velocity (V-meanMCA), superficial temporal artery diameter, radial artery diameter, heart rate, mean arterial blood pressure and facial skin blood flow between the two study days. Results Twenty participants completed the study. We found no difference in the incidence of pituitary adenylate cyclase-activating polypeptide-38-induced headache after glibenclamide (19/20, 95%) compared to placebo (18/20, 90%) (P = 0.698). The area under the curve for headache intensity, middle cerebral artery velocity, superficial temporal artery diameter, radial artery diameter, facial skin blood flow, heart rate and mean arterial blood pressure did not differ between pituitary adenylate cyclase-activating polypeptide-38-glibenclamide day compared to pituitary adenylate cyclase-activating polypeptide-38-placebo day (P > 0.05). Conclusions Posttreatment with 5 '-triphosphate-sensitive K+ channel inhibitor glibenclamide did not attenuate pituitary adenylate cyclase-activating polypeptide-38-induced headache and hemodynamic changes in healthy volunteers. We suggest that pituitary adenylate cyclase-activating polypeptide-38-triggered signaling pathway could be mediated by specific isoforms of sulfonylurea receptor subunits of 5 '-triphosphate-sensitive K+ channels and other types of potassium channels.
KW - Humans
KW - migraine
KW - glyburide
KW - pituitary adenylate cyclase activating polypeptide-38
KW - cranial arteries
KW - CYCLASE-ACTIVATING POLYPEPTIDE
KW - MIGRAINE-LIKE ATTACKS
KW - GENE-RELATED PEPTIDE
KW - ADENYLATE-CYCLASE
KW - TRANSCRANIAL DOPPLER
KW - POTASSIUM CHANNELS
KW - MESSENGER-RNA
KW - ARTERIES
KW - RECEPTORS
KW - PACAP38
U2 - 10.1177/03331024221080574
DO - 10.1177/03331024221080574
M3 - Journal article
C2 - 35301859
VL - 42
SP - 846
EP - 858
JO - Cephalalgia
JF - Cephalalgia
SN - 0800-1952
IS - 9
ER -
ID: 344811221